It looks like wave 2 has completed for SENS. They had a conference today march 9th about some things that were already known to us, but they made some things more clear. Quick summary of this conference:
- Accuracy of the current device is best in class with a MARD of 8.5%
- Medicare National Coverage as of Jan 1, 2021:
- Avg "Supply Cost" (I assume this is for the hardware and consumables) : $1571
- CPT Code 0446T (device insertion) $1,916 average payment
- CPT Code 0448T (device removal and insertion) $1,926 average payment
- Ascencia's commercial world wide investment in Senseonics product marketing is expected to be $30M-$80M per year over 5 years (this is where they got the $250M in the previous conference) and expect the US Ascencia personnel assigned to Senseonics to be in the 80-160 range.
- Eversense is Ascencia's first CGM product and they have exclusive rights to the sales and distribution.
Product Pipeline:
2021+ : Eversense 180 and iCGM/interoperability (integrate with insulin pumps)
2023 : Eversense 365, 1 calibration/week, optional FGM (flash glucose monitoring - no transmitter needed)
2024 : Freedom System, FGM, entire diabetes spectrum covered out to T2 non-insulin using patients.
(credits for this summary to ww.reddit.com/r/senseonics/comments/m18cxq/sens_hc_wainwright_conference_takeaways/)
I'm now looking for a 5 structure to the upside for a wave 3.
Pricetarget for wave 3 is around $10.
How long this will take I'm not sure.
- Accuracy of the current device is best in class with a MARD of 8.5%
- Medicare National Coverage as of Jan 1, 2021:
- Avg "Supply Cost" (I assume this is for the hardware and consumables) : $1571
- CPT Code 0446T (device insertion) $1,916 average payment
- CPT Code 0448T (device removal and insertion) $1,926 average payment
- Ascencia's commercial world wide investment in Senseonics product marketing is expected to be $30M-$80M per year over 5 years (this is where they got the $250M in the previous conference) and expect the US Ascencia personnel assigned to Senseonics to be in the 80-160 range.
- Eversense is Ascencia's first CGM product and they have exclusive rights to the sales and distribution.
Product Pipeline:
2021+ : Eversense 180 and iCGM/interoperability (integrate with insulin pumps)
2023 : Eversense 365, 1 calibration/week, optional FGM (flash glucose monitoring - no transmitter needed)
2024 : Freedom System, FGM, entire diabetes spectrum covered out to T2 non-insulin using patients.
(credits for this summary to ww.reddit.com/r/senseonics/comments/m18cxq/sens_hc_wainwright_conference_takeaways/)
I'm now looking for a 5 structure to the upside for a wave 3.
Pricetarget for wave 3 is around $10.
How long this will take I'm not sure.
코멘트:
looks like wave 2 of wave 3 is in now
